Hunan Er-Kang Pharmaceutical Co Ltd

Hunan Er-Kang Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.15, indicating a relatively conservative capital structure with limited leverage. The company's liquidity position is assessed as medium, with a current ratio of 2.23, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's free cash flow is negative at -395.34 million CNY, and its operating cash flow is 257.68 million CNY, indicating a cash outflow from operations after capital expenditures.

Profitability metrics are weak, with a return on equity of -9.41% and a return on assets of -7.81%, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of 379.82 million CNY and an operating loss of 365.97 million CNY, reflecting a challenging operating environment and potential cost overruns or declining sales.

The company's revenue is concentrated in a single geographic market, China, with no disclosed international operations. This lack of geographic diversification increases exposure to domestic regulatory, economic, and competitive pressures. No segment-specific revenue breakdown is available, but the company's operations are primarily focused on pharmaceuticals.

The company's revenue for the latest period is 1.17 billion CNY, but no growth trajectory is evident from the data provided. The absence of forward-looking guidance and the current operating losses suggest a lack of clear growth drivers or strategic initiatives to reverse the negative trend. The company's capital expenditures of 163.98 million CNY indicate ongoing investment, but the negative free cash flow suggests these investments are not yet generating returns.

The company's risk profile includes a medium liquidity risk due to negative net cash after subtracting total debt. While dilution risk is assessed as low, the company's operating losses and negative free cash flow could pressure the balance sheet and potentially lead to future financing needs. No recent events or filings are disclosed that would indicate a material change in the company's risk profile or strategic direction.

No recent events, such as earnings calls, regulatory filings, or press releases, are disclosed in the available data to provide insight into the company's current strategic direction or operational performance.